GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ICU Medical Inc (NAS:ICUI) » Definitions » Altman Z2-Score

ICUI (ICU Medical) Altman Z2-Score : 2.57 (As of Dec. 13, 2024)


View and export this data going back to 1992. Start your Free Trial

What is ICU Medical Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

ICU Medical has a Altman Z2-Score of 2.57, indicating it is in Grey Zones. This implies that ICU Medical is in some kind of financial stress. If it is below 1.1, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for ICU Medical's Altman Z2-Score or its related term are showing as below:

ICUI' s Altman Z2-Score Range Over the Past 10 Years
Min: 2.51   Med: 8.85   Max: 25.74
Current: 2.57

During the past 13 years, ICU Medical's highest Altman Z2-Score was 25.74. The lowest was 2.51. And the median was 8.85.


ICU Medical Altman Z2-Score Historical Data

The historical data trend for ICU Medical's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ICU Medical Altman Z2-Score Chart

ICU Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.89 10.60 11.33 2.52 2.74

ICU Medical Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.76 2.74 2.69 2.64 2.57

Competitive Comparison of ICU Medical's Altman Z2-Score

For the Medical Instruments & Supplies subindustry, ICU Medical's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ICU Medical's Altman Z2-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where ICU Medical's Altman Z2-Score falls into.



ICU Medical Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

ICU Medical's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.1646+3.26*0.1658+6.72*-0.0009+1.05*0.9079
=2.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2024:
Total Assets was $4,305 Mil.
Total Current Assets was $1,258 Mil.
Total Current Liabilities was $550 Mil.
Retained Earnings was $714 Mil.
Pre-Tax Income was -17.928 + -19.533 + -36.768 + -36.681 = $-111 Mil.
Interest Expense was -27.287 + -26.648 + -26.417 + -26.706 = $-107 Mil.
Total Liabilities was $2,256 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(1258.055 - 549.557)/4305.038
=0.1646

X2=Retained Earnings/Total Assets
=713.986/4305.038
=0.1658

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-110.91 - -107.058)/4305.038
=-0.0009

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(2048.587 - 0)/2256.451
=0.9079

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

ICU Medical has a Altman Z2-Score of 2.57 indicating it is in Grey Zones.


ICU Medical  (NAS:ICUI) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


ICU Medical Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of ICU Medical's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ICU Medical Business Description

Traded in Other Exchanges
Address
951 Calle Amanecer, San Clemente, CA, USA, 92673
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
Executives
Vivek Jain director, officer: Chairman and CEO ICU MEDICAL, INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Christian B. Voigtlander officer: Chief Operating Officer 951 CALLE AMANECER, SAN CLEMENTE CA 92673
David C. Greenberg director 951 CALLE AMANECER, SAN CLEMENTE CA 92887
Daniel Woolson officer: VP, GM-Infusion Capital ICU MEDICAL, INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Virginia Ruth Sanzone officer: VP, General Counsel 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Elisha W Finney director C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
George A Lopez director, officer: Chairman, other: Chairman C/O ICU MEDICAL, 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Smiths Group International Holdings Ltd 10 percent owner C/O SMITHS GROUP PLC, 11-12 ST. JAMES'S SQUARE, 4TH FLOOR, LONDON X0 SW1Y 4LB
Group Plc Smiths 10 percent owner 765 FINCHKEY ROAD, LONDON X0 00000
William Seeger director 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Kolleen T Kennedy director VARIAN MEDICAL SYSTEMS INC, 3100 HANSEN WAY MAIL STOP E327, PALO ALTO CA 94304
Robert S Swinney director C/O ICU MEDICAL, 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Laurie Hernandez director 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Brian Michael Bonnell officer: Chief Financial Officer ICU MEDICAL INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673
Scott E Lamb officer: Controller ICU MEDICAL, INC., 951 CALLE AMANECER, SAN CLEMENTE CA 92673